TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state

Oncogene

Volumn 33, Issue 33, 2014, Pages 4236-4241

  Mori, T ^a   Sato, Y ^a   Miyamoto, K ^a   Kobayashi, T ^a   Shimizu, T ^a,b   Kanagawa, H ^a   Katsuyama, E ^a   Fujie, A ^a   Hao, W ^a   Tando, T ^a   Iwasaki, R ^a   Kawana, H ^a   Morioka, H ^a   Matsumoto, M ^a   Saya, H ^a   Toyama, Y ^a   Miyamoto, T ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

gene mutation; osteoblast differentiation; osteosarcoma; TNF ; tumorigenesis

Indexed keywords

ALKALINE PHOSPHATASE; CASPASE 3; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CD3+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INK4A PROTEIN DEFICIENCY; MACROPHAGE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE C MYC; OSSIFICATION; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UPREGULATION;

MUS;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; DISEASE PROGRESSION; FIBROBLASTS; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; OSTEOBLASTS; OSTEOSARCOMA; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84906278698     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.545     Document Type: Article

References (31)

1. World Health Organization. Ten Statistical Highlights in Global Public Health. World Health Statistics. World Health Organization: Geneva, 2007.
2. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012; 18: 3831-3852.
3. Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G et al. Inflammation, ageing and cancer. Mech Ageing Dev 2009; 130: 40-45.
4. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
5. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3-13.
6. Nakamura T, Matsumine A, Matsubara T, Asamuma K, Niimi R, Uchida A et al. Retrospective analysis of metastatic sarcoma patients. Oncol Lett 2011; 2: 315-318.
7. Dahlin DC. Pathology of osteosarcoma. Clin Orthop Relat Res 1975; 111: 23-32.
8. Kim SJ, Choi JA, Lee SH, Choi JY, Hong SH, Chung HW et al. Imaging findings of extrapulmonary metastases of osteosarcoma. Clin Imaging 2004; 28: 291-300. (Pubitemid 38916584)
9. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003; 84: 151-159. (Pubitemid 37363158)
10. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007; 23: 2-6.
11. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-1543.
12. Bensted JPM, Blackett NM, Lamerton LF. Histological and dosimetric considerations of bone tumour production with radioactive phosphorus. Br J Radiol 1961; 34: 160-175.
13. Sheppard DG, Libshitz HI. Post-radiation sarcomas: a review of the clinical and imaging features in63 cases. Clin Radiol 2001; 56: 22-29. (Pubitemid 32685180)
14. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010; 29: 5687-5699.
15. Waldner MJ, Foersch S, Neurath MF. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8: 1248-1253.
16. Hoejberg L, Bastholt L, Schmidt H. Interleukin-6 and melanoma. Melanoma Res 2012; 22: 327-333.
17. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30: 1005-1014.
18. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245-1250. (Pubitemid 37279838)
19. Paroni G, Henderson C, Schneider C, Brancolini C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J Biol Chem 2001; 276: 21907-21915.
20. Morrison WB. Inflammation and cancer: a comparative view. J Vet Intern Med 2012; 26: 18-31.
21. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822.
22. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009; 206: 1089-1102.
23. Shimizu T, Ishikawa T, Iwai S, Ueki A, Sugihara E, Onishi N et al. Fibroblast growth factor-2 (Fgf2) is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma. Mol Cancer Res 2012; 10: 454-468.
24. Ishikawa T, Shimizu T, Ueki A, Yamaguchi SI, Onishi N, Sugihara E et al. Twist2 functions as a tumor suppressor in murine osteosarcoma cells. Cancer Sci 2013; 104: 880-888.
25. Ueki A, Shimizu T, Masuda K, Yamaguchi SI, Ishikawa T, Sugihara E et al. Up-regulation of Imp3 confers in vivo tumorigenicity on murine osteosarcoma cells. PLoS One 2012; 7: e50621.
26. Yoshikawa K, Takaoka K, Hamada H, Ono K. Clinical significance of bone morphogenetic activity in osteosarcoma. A study of20 cases. Cancer 1985; 56: 1682-1687. (Pubitemid 15228521)
27. Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991; 324: 1585.
28. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674. (Pubitemid 121001702)
29. Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93: 53-62. (Pubitemid 33040860)
30. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13: 863-875. (Pubitemid 33139788)
31. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-185.